Engineered Vancomycin, with Increased Interactions with Peptidoglycan Stem Peptide, Conquers Non-tuberculosis Mycobacteria

Christopher Vennard; Temitope Oropo; Herman O Sintim

doi:10.1021/acs.jmedchem.3c01219

Engineered Vancomycin, with Increased Interactions with Peptidoglycan Stem Peptide, Conquers Non-tuberculosis Mycobacteria

J Med Chem. 2023 Aug 10;66(15):10238-10240. doi: 10.1021/acs.jmedchem.3c01219. Epub 2023 Jul 21.

Authors

Christopher Vennard^{1

2}, Temitope Oropo¹, Herman O Sintim^{1

2

3}

Affiliations

¹ Department of Chemistry, Purdue University, West Lafayette, Indiana 47907, United States.
² Purdue Institute of Inflammation, Immunology and Infectious Disease, Purdue University, West Lafayette, Indiana 47907, United States.
³ Institute for Drug Discovery, Purdue University, West Lafayette, Indiana 47907, United States.

PMID: 37477251
DOI: 10.1021/acs.jmedchem.3c01219

Abstract

Vancomycin-like drugs target peptidoglycan (PG) via binding to C-terminal d-Ala-d-Ala dipeptide. An engineered vancomycin has enhanced affinity for the PG stem peptide, due to probable interactions with a third residue, meso-diaminopimelic acid, in the PG. This engineered vancomycin displays enhanced killing of mycobacteria.

Publication types

Research Support, N.I.H., Extramural

MeSH terms

Anti-Bacterial Agents / metabolism
Anti-Bacterial Agents / pharmacology
Peptidoglycan* / chemistry
Vancomycin Resistance
Vancomycin* / chemistry

Substances

Vancomycin
Peptidoglycan
Anti-Bacterial Agents

Grants and funding

T32 AI148103/AI/NIAID NIH HHS/United States